Tae K Song

This inventor holds 19 USPTO granted patents. Top assignees: Allergan, Inc., Allergan Sales, Inc., Other. Active years: 1996-2003.

USPTO Granted Patents = 19

% Patents Active = 94.7

Average Co-Inventor Count = 3.3

ph-index = 14

Forward Citations = 667(Granted Patents)

Company Filing History:

1 out of 834,411

Other

patents

Years Active: 1996-2003

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6660755 - Substituted diaryl or diheteroaryl methans, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity (2003-12-09),

2. 6455701 - Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity (2002-09-24),

3. 6369100 - Method for inhibiting gene expression promoted by AP1 protein with RAR&bgr; selective retinoids and method for treatment of diseases and conditions with such retinoids (2002-04-09),

4. 6235923 - Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity (2001-05-22),

5. 6225494 - Trisubstituted phenyl derivatives having retinoid agonist or inverse agonist type biological activity (2001-05-01),

6. 6187950 - Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological (2001-02-13),

7. 6037488 - Trisubstituted phenyl derivatives having retinoid agonist, antagonist or (2000-03-14),

8. 6025388 - Method for inhibiting gene expression promoted by AP1 protein with (2000-02-15),

9. 5919970 - Substituted diaryl or diheteroaryl methanes, ethers and amines having (1999-07-06),

10. 5847160 - Acetylenes disubstituted with 2-tetrahydropyranoxy-aryl and aryl of (1998-12-08),

11. 5747542 - Oxo-substituted tetrahydronaphthalene derivatives having retinold and/or (1998-05-05),

12. 5723666 - Oxime substituted tetrahydronaphthalene derivatives having retinoid (1998-03-03),

13. 5698700 - Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or (1997-12-16),

14. 5648503 - Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group (1997-07-15),

15. 5618943 - Acetylenes disubstituted with a 5 OXO substituted tetrahydronaphthyl (1997-04-08),

Title: The Innovative Journey of Tae K Song

Introduction

Tae K Song is a remarkable inventor based in Long Beach, California. With a prolific portfolio consisting of 19 patents, his contributions to the field of biochemistry and pharmacology underscore his ingenuity and commitment to innovation.

Latest Patents

Among his notable achievements are recent patents focused on "Substituted diaryl or diheteroaryl methanes, ethers, and amines having retinoid agonist, antagonist or inverse agonist type biological activity." These groundbreaking inventions explore the biological activities of specific chemical compounds, highlighting their potential implications in therapeutic applications.

Career Highlights

Throughout his career, Tae K Song has made significant strides in the industry while working with esteemed companies such as Allergan, Inc. and Allergan Sales, Inc. His experiences at these organizations have likely played a vital role in shaping his innovative mindset and contributing to his patent portfolio.

Collaborations

Collaboration has been a key aspect of Tae K Song's career. He has worked alongside notable colleagues, including Roshantha A Chandraratna and Min Teng. Their collective efforts within research and development further amplify the impact of their work on the pharmaceutical landscape.

Conclusion

Tae K Song's journey as an inventor reflects a deep passion for innovation, underscored by his extensive patents and collaborations. His contributions not only advance scientific research but also hold promise for future developments in therapeutic solutions. As he continues to explore the intersections of chemistry and biology, the potential for his innovations is boundless.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]